San Francisco, California – insitro has announced the acquisition of CombinAbleAI (https://combinableai.com/). According to the company announcement insitro is an AI therapeutics company that leverages causal biology to understand disease and develop treatments. The company recently announced the acquisition of CombinAbleAI, which will complete its full-stack, modality-agnostic AI platform for drug discovery and design. This integrated platform, known as TherML (Therapeutic Machine Learning), unifies therapeutic design across small molecules, oligonucleotides, antibodies, and other complex biologics. By integrating CombinAbleAI’s physics-informed, AI-driven design with its causal biology platform, insitro aims to optimize both potency and manufacturability simultaneously from the outset of drug discovery. This approach is designed to accelerate the generation of clinic-ready assets and reduce late-stage development risk. insitro applies its platform to identify genetic drivers, prioritize targets, and design medicines for metabolic disease and neuroscience, having raised approximately $800M in capital, including $150M from non-dilutive pharma partnerships.

To learn more about insitro, visit https://www.insitro.com/
Company LinkedIn Page: https://www.linkedin.com/company/insitro/

Company Contact:

insitro
279 East Grand Avenue Suite 200
San Francisco, CA 94080
650-730-7074

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.